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CD40 ligand induced cytotoxicity in carcinoma
cells is enhanced by inhibition of
metalloproteinase cleavage and delivery via a
conditionally-replicating adenovirus
Taha Elmetwali, Peter F Searle, Iain McNeish, Lawrence S Young, Daniel H Palmer*
Abstract
Background: CD40 and its ligand (CD40L) play a critical role in co-ordinating immune responses. CD40 is also
expressed in lymphoid malignancies and a number of carcinomas. In carcinoma cells the physiological outcome of
CD40 ligation depends on the level of receptor engagement with low levels promoting cell survival and high
levels inducing cell death. The most profound induction of cell death in carcinoma cells is induced by membrane-
bound rather than recombinant soluble CD40L, but like other TNF family ligands, it is cleaved from the membrane
by matrix metalloproteinases.
Results: We have generated a replication-deficient adenovirus expressing a mutant CD40L that is resistant to
metalloproteinase cleavage such that ligand expression is retained at the cell membrane. Here we show that the
mutated, cleavage-resistant form of CD40L is a more potent inducer of apoptosis than wild-type ligand in CD40-
positive carcinoma cell lines. Since transgene expression via replication-deficient adenovirus vectors in vivo is low,
we have also engineered a conditionally replicating E1A-CR2 deleted adenovirus to express mutant CD40L,
resulting in significant amplification of ligand expression and consequent enhancement of its therapeutic effect.
Conclusions: Combined with numerous studies demonstrating its immunotherapeutic potential, these data
provide a strong rationale for the exploitation of the CD40-CD40L pathway for the treatment of solid tumours.
Background
CD40, a member of the tumour necrosis factor receptor
(TNFR) superfamily, and its ligand (CD40L/CD154) play
a fundamental role in co-ordinating immune responses
[1]. CD40 is expressed on normal B cells, monocytes
and dendritic cells (DC) and interaction with its ligand
promotes dendritic cell maturation, upregulation of co-
stimulatory molecules and secretion of immunostimula-
tory cytokines. Thus, CD40 stimulation can effect the
key elements required for generation of antigen-specific
cytotoxic T-cell responses. On this basis, engagement of
CD40 on DC to induce anti-tumour immune responses
is a prolific area of research and both recombinant
soluble CD40 ligand and CD40 agonist antibodies have
entered clinical trials.
We, and others, have demonstrated that in addition to
immune cells, CD40 is expressed in malignant haemo-
poietic cells and a number of carcinomas [2]. In carci-
noma cells the level of CD40 engagement influences the
physiological outcome with low levels of ligation pro-
moting cell survival/proliferation and high levels indu-
cing growth arrest/apoptosis [3-5]. The precise form of
the CD40 stimulus affects these responses with the most
profound effects in carcinoma cells being induced by
membrane-bound (mCD40L) rather than recombinant
soluble CD40L (rsCD40L) [6,7].
We have previously found that rsCD40L can stimulate
survival signalling pathways (including PI-3-kinase and
ERK/MAPK) and induces apoptosis in carcinoma cells
only in the presence of either protein synthesis inhibi-
tion, cytotoxic drugs or inhibitors of the PI3K/mTOR
* Correspondence: d.palmer@bham.ac.uk
Cancer Research UK Institute for Cancer Studies, School of Cancer Sciences,
University of Birmingham, B15 2TT, UK
Elmetwali et al. Molecular Cancer 2010, 9:52
http://www.molecular-cancer.com/content/9/1/52
© 2010 Elmetwali et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
and/or ERK pathways [8]. In contrast, membrane-bound
CD40L delivered by co-culture of carcinoma cells with
CD40L-expressing fibroblasts induces apoptosis without
the requirement for any other agent [6,7]. Thus, as a
potential anti-cancer therapy, membrane-bound CD40L
appears to be more attractive than the recombinant
soluble form. As a means of delivering membrane-
bound CD40L in a form that may be clinically applic-
able, we have generated a replication-deficient recombi-
nant adenovirus encoding human CD40L (RAdCD40L),
which results in expression of ligand at the cell mem-
brane. Further, based on our previous observation that
Fas ligand mutated to resist cleavage from the cell mem-
brane delivers a more potent apoptotic stimulus than
wild-type FasL, we have generated a mutant CD40L that
is resistant to cleavage by matrix metalloproteinases.
The direct effect of wild-type and cleavage-resistant
CD40L on cell survival was examined in CD40-positive
carcinoma cell lines. Since transgene expression via
replication-deficient adenovirus vectors in vivo is low,
we have also engineered an E1A-deleted conditionally
replicating adenovirus to express mutant CD40L with
the aim of amplifying its expression and consequently
its therapeutic effects.
Methods
Adenoviral construction and generation of
CD40 ligand mutant
To generate a replication-deficient adenovirus expres-
sing CD40L, human cDNA encoding wild-type CD40L
was cloned in-frame under a CMV promoter into the
pAdTrack-CMV vector. After confirming CD40L
expression in HEK293 cells, this vector or the empty
pAdTrack-CMV vector were homologously recombined
with an E1-, E3- deleted adenoviral AdEasy vector as
described by He et al (1998) to generate RAdCD40L or
GFP control virus (RAdMock) [9]. Virus was packaged
in the E1-expressing cell line, 911, and purified by cae-
sium chloride banding. Virus titres were determined
using the TCID50 method, based on the development of
CPE in HEK293 cells using serial dilutions to estimate
adenovirus stock titre.
To generate a CD40L mutant lacking the amino acid
sequence (110SFEMQKG116) the Quick Change site-direc-
ted mutagenesis (Strategene Europe, Amsterdam, Nether-
lands) was utilized using forward: 5’GAGGAGACGAA
GAAAGAAGATCAGAATCCTCAAATTGCGGC 3’ and
reverse: 5’GCCGCAATTTGAGGATTCTGATCTTCTTT
CTTCGTCTCCTC 3’ primers in a PCR reaction accord-
ing to the manufacturer’s instructions. Following sequen-
cing of the deletion mutation, a RAd expressing the
CD40L mutant (RAdncCD40L) was then generated as
described above.
To generate replication-competent adenoviruses
expressing either ncCD40L mutant or GFP, forward:
5’GTCCACTGTCGCCGCCACAAG 3’ and reverse:
5’GCTGCGCCTTTGGCCTAATACC 3’ primers were
used to amplify the 634 bp DNA fragment from an
Ad5E3 DNA construct (originally generated by cloning
the 5665 bp of the HindIII fragment of Ad5 into
the pUC19 plasmid) upstream of the 5’ end of the AdE3
6.7 k fragment for replacing the 6.7 k and 19 k fragments
of the AdE3 region. The amplified fragment contains a
BsiWI site at the 5’ position. To fuse the ncCD40L into
the 634 bp amplified fragment, a ncCD40L forward pri-
mer: 5’ GTATTAGGCCAAAGGCGCAGCTTCGAAC-
CACCatgatcgaaacatacaaccaaacttc 3’ containing 32 bp at
the 5’ end overlapping with the 3’ end of the amplified
634 bp fragment and a reverse primer 5’CAGCAATTG-
GATCctgttcagagtttgagtaagccaaag 3’ with an artificial
MfeI site at the 3’ region were used to amplify the
ncCD40L from the pAdTrack-CMV-ncCD40L construct.
The amplified ncCD40L was then fused to the 634 bp
fragment of the AdE3 region utilizing the forward:
5’GTCCACTGTCGCCGCCACAAG 3’ and the reverse:
5’CAGCAATTGGATCctgttcagagtttgagtaagccaaag 3’ pri-
mers. The AdE3-ncCD40L fusion fragment was then
cloned into the Ad5E3 DNA construct between BsiWI
and MfeI restriction sites. The resultant construct was
homologously recombined with an E1-deleted adenovirus
in E. coli BJ5183 cells in order to replace the 6.7 k and 19
k fragments of the AdE3 region with the ncCD40L gene.
To provide the E1-deleted AdncCD40L with an
E1-encoding cDNA, a second homologous recombination
was carried out in HEK 293 cells with a viral vector con-
taining the AdE1 gene with a deletion mutation within
the CR2 region (dl922-947). Following several rounds of
adenoviral selection on human alveolar basal epithelial
carcinoma A549 cells, which lack the E1 gene, replication
competent adenoviruses expressing either ncCD40L
mutant or GFP were extracted from single colony infec-
tion and amplified in A549 cells for adenoviral stock
preparation.
For in vitro infections, cells were seeded in 10% FCS
D-MEM complete media at 4,000 cells/well in a 96-well
plate for cell viability assay, or 3 × 105 cells/30 mm dish
for western blotting analysis. Cells were infected in 10%
FCS D-MEM for 2 hours at 37°C with the appropriate
MOI of adenovirus. Culture medium was then replaced
by fresh medium and cells incubated at 37°C until
assessed.
RNA extraction and RT-PCR analysis
RNA was extracted using the RNAzol reagent (Biogen-
esis Ltd, Poole UK) and cDNA was synthesised using
RETROscript® RNase reverse transcription kit (Ambion
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Europe) according to the manufacturer’s instructions.
RT-PCR was performed using PLATINUM™ Taq DNA
polymerase (Invitrogen) utilising the human CD40-spe-
cific forward: 5’AGTGACTGCACAGAGTTCACT 3’
and reverse 5’CAAGAGGATGGCAAACAGGAT 3’ pri-
mers. To confirm the CR2 mutation deletion (dl922-
947), forward primers, 5’ CTGCCACGAGGCTGGC 3’
and 5’ CCACACACGCAATCACAGG 3’ spanning
either a DNA sequence within the CR2-deletion (dl922-
947) or downstream of the deletion respectively were
used in RT-PCR utilizing the general reverse primer 5’
CCACACACGCAATCACAGG 3’ to discriminate ade-
novirus carrying wild type E1A CR2 from that carrying
the E1A CR2 deletion mutant. For RT-PCR, the amount
of cDNA template used was adjusted on the basis of
amplification with primers specific for human GAPDH:
forward 5’ CCTCCAAAATCAAGTGGGGCG 3’ and
reverse 5’ACCACCAGGTGCTCAGTGTAG 3’.
Pharmacological inhibitors
Cells were seeded in 10% FCS D-MEM complete media
at 4,000 cells/well in a 96-well plate infected with the
appropriate MOI of either RAdMock or RAdCD40L or
left uninfected as a control. Twenty-four hours post-
infection cells were treated with 30 μM of the metallo-
proteinase inhibitor, MMPI II (Calbiochem) or left
untreated for a further 24 hours. Cell viability was then
determined by WST-1 assay.
WST-1 cell viability assay
Cells were plated in 96-well plates at 4000 cell/100 μl/
well and incubated at 37°C. Cell viability was assessed
by adding WST-1 reagent (Roche) to the culture med-
ium at 1:10 dilution. Cells were incubated at 37°C and
the optical density was measured by microplate ELISA
reader at l450 every 2 hours to a maximum of 6 hours.
The amount of the formazan formed directly correlates
to the number of metabolically active cells.
Analysis of cell surface CD40L expression
For CD40L expression, cells were infected with
RAdCD40L or RAdncCD40L at 100 MOI for 24 hours.
Cells were washed and incubated on ice for 45 minutes
with mouse anti-CD40L-APC conjugate antibody or
mouse isotype-APC antibody conjugate or left without
treatment. Cells were then washed, fixed in 1% PFA and
analysed by flow cytometry.
Annexin V staining of apoptotic cells
Following the relevant treatment, cells were harvested
and stained with Annexin V-APC according to the man-
ufacturer’s instruction (BD Biosciences). The percentage
of Annexin V-APC positive cells was determined within
1 × 104 cells of the population by flow cytometry.
sCD40L enzyme-linked immunosorbent assay (ELISA)
EJ cells were plated in 96-well plates at 4000 cell/100 μl/
well and incubated at 37°C in 10% FCS D-MEM med-
ium. Culture media were collected from RAdCD40L,
RAdncCD40L, RAdMock, uninfected control and cell-
free medium control 24 and 72 hours post-infection and
analysed for human sCD40L by ELISA assay (Biosource
International, USA) according to the manufacturer’s
instructions.
Western blot analysis and antibodies
Anti-CD40L antibody was from Santa Cruz Biotechnol-
ogy. Monoclonal mouse anti- b-actin and GFP antibodies
were from Sigma and Sterillin, UK respectively. For
immunoblotting, 10-30 μg protein was separated by SDS-
PAGE and transferred onto nitrocellulose membranes
and blocked with 5% non-fat milk. Membranes were
incubated overnight at 4°C with primary antibody and
after washing, incubated for 1 hour at room temperature
with the appropriate secondary antibody. Membranes
were washed followed by enhanced chemiluminescence
(Amersham Biosciences).
Results
Adenovirus-delivered CD40L directly induces apoptosis in
CD40 positive carcinoma cells
We first constructed a replication-deficient adenovirus
to express human wild-type CD40 ligand, designated
RAdCD40L, using the AdEasy system (Quantum Bio-
technologies) and methods as published by Chuan He
and co-workers [9]. Expression of CD40L from this vec-
tor was confirmed by western blotting for CD40L pro-
tein in lysates of infected cells (Figure 1A).
The effect of RAdCD40L on the viability of a panel of
epithelial cell lines was then examined. The bladder car-
cinoma line, EJ, and the gastric carcinoma line, AGS,
are CD40 receptor-positive, whilst the CD40-negative
nasopharyngeal carcinoma line, HONE-1, was used as a
negative control (Figure 1B). Each cell line was infected
with either RAdMock or RAdCD40L or left uninfected
as a negative control and 48 hours later cell viability
was assessed by WST-1 assay. RAdCD40L infection
induced a modest reduction in viability of the CD40-
positive EJ and AGS but, as expected, had no effect on
the CD40-negative HONE-1 cells (RAdMock vs.
RAdCD40L: AGS, p = 0.0011; EJ, p = 0.0034; HONE-1,
p = 04818) (Figure 1C).
Inhibition of CD40L cleavage from the cell membrane
enhances its cytotoxicity
Ligands of the TNF family are biologically active as self-
assembling, non-covalently bound trimers that are natu-
rally expressed on the cell surface as membrane-bound
structures but are proteolytically cleaved into soluble
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Figure 1 Adenovirus-delivered CD40L directly induces growth inhibition in CD40 positive carcinoma cells. (A) Analysis of CD40L and GFP
expression from RAdCD40L and RAdMock viruses. HEK 293 cells were infected with RAdMock or RAdCD40L. Two days later cell lysates were
probed with anti-CD40L and anti-GFP specific antibodies. (B) Analysis of the expression of CD40 receptor. 30 μg of total protein lysate from the
carcinoma cell lines EJ, AGS and HONE-1 were examined for CD40 receptor expression by Western blotting using a specific anti-CD40 antibody.
b-actin expression was determined as a loading control. (C) Effect of RAdCD40L on cell viability. The cancer cell lines AGS, EJ and HONE-1 were
infected with 25 or 100 MOI of either RAdMock (RAdM) or RAdCD40L (RAdL) or left without infection. Forty-eight hours later cell viability was
assessed by WST-1 assay. Results are the mean of triplet samples +/- SD. Two-tailed t-test RAdMock vs. RAdL: AGS, p = 0.0011; EJ, p = 0.0034;
HONE-1, p = 0.4818.
Elmetwali et al. Molecular Cancer 2010, 9:52
http://www.molecular-cancer.com/content/9/1/52
Page 4 of 12
forms by members of the ADAM metalloproteinase
(MP) family, a process which may serve a negative regu-
latory function in the signalling induced through recep-
tor ligation [10]. Indeed, we have previously found that
a RAd expressing a mutated FasL lacking the MP clea-
vage site is a much more potent inducer of carcinoma
cell death than wild type FasL [11].
Since CD40L is also subject to proteolytic cleavage we
hypothesised that inhibition of CD40L cleavage may
enhance its anti-tumour effects [12]. In this study we
have sought to identify the CD40L MP cleavage site
with a view to generating mutated CD40L that is resis-
tant to cleavage from the cell membrane.
In order to first confirm that inhibition of MP cleavage
of CD40L does, indeed, enhance its cytotoxicity, EJ cells
were infected with RAdCD40L and 24 hours later were
treated with MPI II, a potent, reversible, broad-range
inhibitor of a number of MPs including MP-1, MP-3,
MP-7, and MP-9. Treatment of RAdCD40L-infected cells
with MPI II resulted in a significant incremental increase
in cell death compared to RAdCD40L-infected cells in
the absence of MPI (p = 0.0041). In uninfected cells MP
inhibition alone did not affect cell viability. Moreover,
and as expected, MPI II had no effect on the viability of
cells treated with rsCD40L (Figure 2). These results
strongly suggest that CD40L is a more potent inducer of
carcinoma cell death when its expression is retained at
the cell membrane. On this basis, we next sought to iden-
tify the CD40L cleavage site that is targeted by MP
enzymes.
Identification and mutation of the CD40L cleavage site
Previous studies have shown that deletion of the Fas
ligand region that includes amino acid 128-131 retains
its receptor binding capacity but blocks release of solu-
ble FasL from the cell membrane [11]. To identify the
putative MP cleavage site within CD40L, we performed
amino acid sequence alignment between the published
FasL cleavage site and CD40L, identifying a region in
the extracellular domain of CD40L with significant
homology with the known cleavage site of FasL
(128EKQI131) (Figure 3A). In addition to this region of
homology, more supportive information was obtained
from published studies of bacterial expression and puri-
fication of the CD40L extracellular domain (44-261
amino acids), which was consistently associated with
two protein fragments running at molecular weights of
18- and 14-kDa on SDS-PAGE electrophoresis. Further
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Figure 2 The effect of matrix metalloproteinase inhibitors (MPI) on RAdCD40L-induced cell death. EJ cells were infected with 100 MOI of
either RAdMock (RAdM) or RAdCD40L (RAdL) or left without infection, or cultured with 1 μg/ml soluble CD40L. Twenty-four hours later cells
were treated with 30 μM of MPI II or left without treatment for a further 24 hours. Cell viability was assessed by WST-1 assay. Results are the
mean of triplet samples +/- SD. Two-tailed t-test RAdL vs. RAdL+MPI: p = 0.0041.
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Figure 3 Identification and mutation of the CD40L cleavage site leads to retention of ligand at the cell membrane. (A) Amino acid
alignment of FasL and CD40L. Alignment identified a region in the extracellular domain of CD40L (EMQK) with significant similarity to the
cleavage site of FasL (EKQI). CD40L mutant (ncCD40L) is not cleaved into soluble CD40L. EJ cells were infected with 100 MOI of either RAdMock
(RAdM) or RAdCD40L (RAdL) or RAdncCD40L (RAdncL) or left without infection. (B) Samples were collected from the culture media 24 and 72
hours post-infection for sCD40L ELISA assay. Results represent a mean of triplet samples +/- SD. Two-tailed t-test RAdL vs. RAdncL: 24 h,
p = 0.0067; 72 h, p < 0.0001. (C) CD40L expression was examined by western blot 72 hours after infection. b-actin was used as a loading control.
(D) Adenovirus-delivered CD40L is expressed on the cell membrane. EJ cells were infected with 100 MOI of either RAdCD40L (wild-type) or
RAdncCD40L (mutated cleavage resistant) for 28 hours. Harvested cells were incubated with mouse anti-CD40L-APC conjugated antibody or
isotype control and then analysed by flow cytometry.
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purification and amino acid sequence analysis showed
that the 18-kD fragment was active in the context of
CD40 biology and that this sequence starts from the
amino acid 108ENSFEMQKG116, which contains the
same sequence identified by alignment with the FasL
cleavage site [13]. These observations suggest this to be
the most likely CD40L cleavage site. On this basis, we
next generated a mutant CD40L with an amino acid
deletion mutation encompassing the 110SFEMQKG116
sequence and engineered this into a RAd vector.
To generate a clone of pAdTrack-CMV-CD154
(CD40L) with the amino acid sequence 110SFEMQKG116
deletion mutation we utilised the quickchange site-direc-
ted mutagenesis (SDM) reagent as described in Materials
and Methods utilising forward and reverse primers of
CD40Lde110-116F and CD40Lde110-116R spanning the
targeted deletion site. Sequence analysis confirmed suc-
cessful generation of the deletion mutation and the
mutant sequence was cloned into a replication-deficient
adenovirus vector, designated RAdncCD40L.
To confirm that the deletion mutant was resistant to
MP cleavage, EJ cells were infected with RAdCD40L or
RAdncCD40L and supernatant was harvested and ana-
lysed for presence of soluble ligand using a sCD40L
ELISA assay (Figure 3B). CD40L protein expression was
also assessed by western blotting of cell lysates from the
same samples (Figure 3C). A significant quantity of
sCD40L was detected in the supernatant of RAdCD40L
infected cells with the amount increasing over time.
However, no soluble ligand was detected in the superna-
tant of RAdncCD40L infected cells, confirming that
deletion of the 110SFEMQKG116 sequence blocked clea-
vage of CD40L from the cell membrane despite high
levels of ligand expression on western blotting
(RAdCD40L vs. RAdncCD40L at 72 hours, p < 0.0001).
The level of ncCD40L protein was higher than that of
wild-type ligand assessed by western blot analysis sug-
gesting that a significant amount of CD40L expressed
from the RAdCD40L was released into the culture med-
ium. Furthermore, retention of CD40L at the cell mem-
brane was confirmed by flow cytometry. A panel of cell
lines infected with wild-type CD40L demonstrated
ligand expression at the membrane. However, infection
with the equivalent MOI of non-cleavable CD40L
resulted in significantly greater membranous ligand
expression (Figure 3D).
We next sought to investigate the ability of mem-
brane-bound CD40L to induce apoptosis in CD40-posi-
tive carcinomas. Unlike soluble CD40L, RAd-delivered
CD40L is able to directly induce apoptosis in CD40-
positive carcinoma cells (EJ, AGS) as assessed by
Annexin V staining. Furthermore, significantly higher
levels of apoptosis are induced by cleavage-resistant
ligand (RAdncCD40L vs. RAdCD40L: EJ, p = 0.0014;
AGS, p = 0.0022). The requirement for CD40-CD40L
interaction for apoptosis was confirmed by an absence
of effect in CD40-negative HeLa cells (Figure 4;
p = 0.6560).
Thus RAdncCD40L produces CD40 ligand expressed
on the membrane of infected cells, fails to generate
soluble ligand and demonstrates significantly enhanced
apoptosis induction compared to RAdCD40L without
the requirement for protein synthesis inhibition.
Delivery of membrane-bound CD40L via a conditionally
replicating adenovirus
Here we have demonstrated the ability of a mutant non-
cleavable CD40L delivered via a replication-deficient
adenovirus vector to directly induce cell death in CD40
expressing carcinoma cells. However, it is recognised
that such vectors generally result in low-level transgene
expression in vivo. We hypothesised that the generation
of a replication-competent adenovirus expressing the
ncCD40L would have significantly greater cytotoxic
effects through amplified expression of the membrane-
bound ligand and dissemination within the tumour
environment to enable the paracrine stimulation of
CD40, as well as through the effects of viral oncolysis.
For wild-type adenovirus to replicate normally the viral
E1A early protein, through its CR2 domain, is required to
bind to and inactivate the retinoblastoma protein (pRb)
in the infected host cell in order to subvert anti-viral
growth arrest responses. Thus, deletion of this domain
abrogates viral replication in normal cells with an intact
pRb response. However, in most human cancers the pRb
pathway is perturbed. As a result of this, replication of an
adenovirus with a CR2 dl922-947 deletion mutation in
the E1A gene is restricted to tumour cells and virus repli-
cation results in tumour cell lysis, propagating infective
virus throughout the tumour [14].
In order to establish the rationale for its incorporation
into a replicating adenovirus, we first demonstrated that
the degree of cell death induced by ncCD40L is dose-
dependent indicating that amplification of its expression
will increase cell death (RAdncCD40L 10 MOI vs. 100
MOI: p = 0.0001) (Figure 5A). This was further corrobo-
rated by co-infecting EJ cells with RAdncCD0L and an
E1A CR2-deleted adenovirus (E1A-ΔCR2). The dose of
each virus individually was insufficient to induce cell
death. However, the combination resulted in increased
expression of CD40L presumably through viral proteins
expressed by the E1A-ΔCR2 supporting replication of
the RAd, and which resulted in cell death (E1A-CR2
+RAdMock vs. E1A-CR2+RAdncCD40L: p = 0.0015)
(Figure 5B and 5C).
On this basis, we generated a CR2 dl922-947 deleted
adenovirus expressing the ncCD40L, designated
E1AD24ncCD40L, by replacing the 6.7 k and the 19 k
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fragments within the E3 region with the ncCD40L gene,
driving its expression from the endogenous E3 promo-
ter. Expression of ncCD40L from E1AD24ncCD40L was
verified by immunoblotting lysates of infected EJ cells.
Further, the level of ligand expression was compared
with that achieved by the replication-deficient vector.
The replicating vector resulted in significantly greater
expression of CD40L, with an MOI of 5 exceeding
the level achieved by even 100 MOI RAdncCD40L
(Figure 6A).
We next examined the effect of E1AD24ncCD40L on
the viability of CD40-positive carcinomas. Firstly, the
CD40 status of bladder carcinoma cells, EJ, Hela cells
and human alveolar basal epithelial carcinoma cells,
A549, was determined. The level of CD40 expression in
A549 cells was very low compared to EJ cells and, as
expected, Hela cells did not express CD40 at all
(Figure 6B). These cell lines were then infected with
either E1AD24GFP or E1AD24ncCD40L and cell viabi-
lity was assessed. E1AD24ncCD40L infection resulted in
significant cell death in EJ cells and to a lesser extent in
A549 cells in a time-dependant manner consistent with
increasing ligand expression over time, and in propor-
tion with the degree of CD40 receptor expression in
these cell types (E1AD24GFP vs. E1AD24ncCD40L: EJ,
p < 0.0001; A549, p = 0.0460). No significant cell death
GFP positive cells
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Figure 4 Membrane-bound expression of CD40L induces apoptosis in CD40-positive carcinomas. EJ, AGS and HeLa cells were infected
with 100 MOI RAdMock, RAdCD40L or RAdncCD40L, or treated with soluble CD40L (1 μg/ml) or left without treatment for 48 hours. Apoptotic
cells were assessed by staining with Annexin V-APC and analysis by flow cytometry. Results are a mean of triplet samples ± SD. Two-tailed t-test
RAdL vs. RAdncL: EJ, p = 0.0014; AJS, p = 0.0022; HeLa, p = 0.6560.
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Figure 5 RAd-delivered CD40L acts in synergy with conditionally replicating adenovirus. (A) RAdncCD40L cytotoxicity is dose-dependent.
EJ cells were infected with 0, 10 or 100 MOI RAdncCD40L and 48 hours later cell viability was assessed by WST-1 assay. Results are the mean of
triplet samples +/-SD. Two-tailed t-test 10 MOI vs. 100 MOI: p = 0.0001. Co-infection with RAdncCD40L and E1AΔCR2 enhances ncCD40L
expression and cytotoxicity. (B) EJ cells were infected with 1 MOI RAdncCD40L and co-infected with 0, 0.1 or 1 MOI E1AΔCR2. Cell lysates were
harvested at 48 and 120 hours and 20 μg total protein was blotted for ncCD40L. (C) EJ cells were plated in 96-well plates and infected with 1
MOI of either RAdncCD40L or RAdMock or left uninfected; simultaneously cells were infected with 0.1 MOI E1A ΔCR2 and 120 hours later cell
viability was assessed by WST-1 assay. Results are the mean of triplet samples +/-SD. Two-tailed t-test E1A-CR2+RAdM vs. E1A-CR2+RAdncL:
p = 0.0015.
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Figure 6 Delivery of membrane-bound CD40L via a conditionally replicating adenovirus. (A) Expression of ncCD40L by E1AD24ncCD40L.
A549 cells were infected with 5 MOI E1AD24ncCD40L or E1AD24GFP or left uninfected for 48 hours. In parallel, cell were infected with
RAdncCD40L (5 or 100 MOI). 10 μg of total protein lysates were blotted for ncCD40L. (B) Analysis of CD40 expression. Total protein lysates from
EJ, Hela and A549 cells were harvested and CD40 expression was examined by western blot. b-actin was used as a loading control. (C) Effect of
E1AD24ncCD40L on cell viability. EJ, Hela and A549 cells were infected with 5 MOI of either E1AD24GFP (E1AGFP) or E1AD24ncCD40L (E1AncL)
or left without infection for 36 hours. Cell viability was then assessed by WST-1 assay. Results are the mean of triplet samples +/- SD. Two-tailed
t-test E1A-GFP vs. E1A-ncL: EJ, p < 0.0001; HeLa, p = 0.2879; A549, p = 0.0460.
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was observed in the CD40-negative Hela cells
(p = 0.2879), the time points studied being too early for
viral oncolysis, further confirming that the cell death in
EJ is likely to be due to the robust expression of
ncCD40L achieved by this vector (Figure 6C).
Discussion
We have generated an E1-, E3- deleted replication defi-
cient adenovirus expressing CD40L and shown that
CD40-positive carcinoma cell lines are sensitive to
CD40L-induced cell death. Cell death was further
enhanced by inhibition of matrix metalloproteinases
indicating that membrane-bound ligand is likely to be
more potent in inducing carcinoma cell death. In com-
mon with other TNF ligands, CD40L is exposed to clea-
vage by the action of MPs, liberating soluble CD40L
[12]. Previous studies have generated a mutated FasL
lacking the metalloproteinase cleavage site, which is a
more potent inducer of carcinoma cell death than wild
type FasL [11]. To generate a non-cleavable CD40L
mutant we identified the CD40L cleavage site by align-
ment of the published amino acid sequence of the FasL
cleavage site and the CD40L sequence. This identified
the 108ENSFEMQKG116 region in the extracellular
domain of CD40L, which exhibited significant homology
with the cleavage site of FasL (128EKQI131). Along with
other corroborative evidence, this encouraged us to gen-
erate a mutant CD40L with this sequence deleted by
site directed mutagenesis. A RAd expressing this mutant
was then constructed (RAdncCD40L) and its resistance
to MP cleavage was confirmed. As expected this virus
failed to generate soluble ligand, resukted in a higher
level of membrane-bound ligand expression, and
induced greater cell death than wild-type ligand in
CD40-positive carcinoma cells.
Soluble CD40L is known to induce transient signalling
including both pro-survival and pro-apoptotic signals,
and induction of cell death in this context requires inhi-
bition of de novo protein synthesis to inhibit survival
signals and promote apoptosis [6,15-17]. Membrane-
bound CD40L, on the other hand, through sustained
activation of TRAF3-dependent JNK signalling and sup-
pression of TRAF6-dependent survival signals, is able to
directly induce cell death without the requirement for
protein synthesis inhibition [[7], and Elmetwali et al,
J Immunol, 2010. In Press]. Thus, the greater cytotoxi-
city of ncCD40L is likely to be due to retention of
ligand at the cell membrane inducing more sustained
pro-apoptotic signals than wild-type CD40L, the latter
being susceptible to cleavage into soluble CD40L, a pro-
cess that may serve a regulatory role in physiological
TNF family ligand signalling.
In order to further enhance the anti-cancer potency of
ncCD40L, we predicted that a replication-competent
adenovirus expressing ncCD40L would induce greater
cytotoxicity than a replication-deficient vector by
increasing expression and dissemination of transgene as
well as through the contribution of viral oncolysis.
For human adenovirus replication, the conserved
region 2 (CR2) domain within E1A is required to med-
iate pRb binding and inactivation [18,19]. Thus, a dele-
tion mutation, dl922-947, within CR2 permits virus
replication in a broad range of cancer cells with
abnormalities in cell-cycle checkpoints [17]. We have
generated a dl922-947 mutant adenovirus and further
modified it to express ncCD40L by replacing the 6.7 k
and 19 k fragments of the E3 region. The E3 transcrip-
tion unit is an ideal site for transgene insertion since it
is non-essential for viral replication in vitro [20-22]. The
6.7 k and the 19 k fragments were chosen as a site for
insertion of the ncCD40L gene because they are adja-
cent to one another in the viral genome, are encoded by
the same E3 mRNA, and have overlapping open reading
frames [23]. The E3 6.7 k protein functions in concert
with adenoviral receptor internalization and degradation
complex (RID) to reduce TRAIL receptor-1 and -2 cell
surface expression [24]. Since CD40L cytotoxicity may,
at least in part, be mediated through up-regulation of
TNF family ligands including TRAIL, the deletion of E3
6.7 K may be advantageous to CD40L-mediated effects
through retention of TRAIL receptor expression (17).
The 19 k protein is known to bind MHC class I mole-
cules in the endoplasmic reticulum (ER), inhibiting their
transport to the infected cell surface [25]. Therefore,
wild-type virus is able to evade detection and eradica-
tion by Ad-specific cytotoxic T lymphocytes (CTL).
Thus, the loss of the 19 k protein should ensure that
normal cells infected with the virus are ‘visible’ to host
CTLs and efficiently eradicated. Incorporation of
ncCD40L into this vector resulted in dramatically
increased ligand expression compared to the replication-
deficient counterpart and this translated into signifi-
cantly greater induction of cell death in a CD40-depen-
dent manner.
Previous studies have demonstrated that CD40 ligation
on carcinoma cells induces up-regulation of antigen pro-
cessing and presentation with consequent enhanced
recognition of these cells by specific cytotoxic T lym-
phocytes and induces strong systemic anti-tumour cyto-
toxic T cell activity in tumour bearing mice. Further,
co-delivery of immature dendritic cells with RAdCD40L
induces strong anti-tumour immunity, while treatment
with immature DCs alone has no effect in a number of
tumour models [26-29]. Our demonstration of the abil-
ity of adenovirus-delivered CD40L to suppress prolifera-
tion and induce apoptosis in carcinoma cells provides
further rationale for exploiting the CD40-CD40L path-
way for the treatment of solid tumours and suggests an
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advantage over other immunostimulatory cancer therapy
approaches, particularly through generation of a mem-
brane-bound mutant and through enhanced delivery via
a conditionally-replicating vector. Taken together, the
CD40 pathway provides an opportunity to harness dif-
ferent anti-cancer approaches into one therapy and
offers an attractive option for clinical trials. Our findings
demonstrate clear advantages of our mutant CD40L
compared to rsCD40L in terms of directly inducing
death in infected cancer cells.
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